UnknownPhase 2NCT04600947
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Studying Primary mediastinal large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Principal Investigator
- Yuankai Shi, MDCancer Institute and Hospital, Chinese Academy of Medical Sciences
- Intervention
- LP002(drug)
- Enrollment
- 69 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (7)
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
- Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
- The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- Wuhan University People's Hospital, Wuhan, Hubei, China
- Hunan Cancer Hospital, Changsha, Hunan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04600947 on ClinicalTrials.govOther trials for Primary mediastinal large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07168486CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasUniversity of Maryland, Baltimore
- RECRUITINGPHASE2NCT06500273Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLAllogene Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT05757700Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05653271ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesAcepodia Biotech, Inc.
- ACTIVE NOT RECRUITINGNCT06024694Primary Mediastinal Large B-cell Lymphoma With CNS InvolvementIRCCS San Raffaele
- RECRUITINGNCT05366569Bio-CAR-T BS StudyAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- ACTIVE NOT RECRUITINGPHASE3NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04745949PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyM.D. Anderson Cancer Center
See all trials for Primary mediastinal large B-cell lymphoma →